{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "patients with primary cutaneous melanoma (\u22651 mm with Clark level \u2265III, or any thickness with Clark level \u2265IV) were randomly assigned in a 4:6 ratio"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with primary cutaneous melanoma (\u22651 mm with Clark level \u2265III, or any thickness with Clark level \u2265IV) were randomly assigned"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned in a 4:6 ratio to WE plus observation (WEO) with delayed CLND for nodal recurrence, or to WE plus LM/SNB with immediate CLND for SN metastasis"
      },
      "Objective": {
        "score": 1,
        "evidence": "The objective of this study was to evaluate, in an international multicenter phase III trial, the accuracy, use, and morbidity of intraoperative lymphatic mapping and sentinel node biopsy (LM/SNB) for staging the regional nodal basin of patients with early-stage melanoma."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Early morbidity of LM/SNB was evaluated by comparing complication rates between the 2 treatment groups."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "patients with primary cutaneous melanoma (\u22651 mm with Clark level \u2265III, or any thickness with Clark level \u2265IV) were randomly assigned in a 4:6 ratio"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Trial accrual was completed on March 31, 2002, after enrollment of 2001 patients."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Initial SN identification rate was 95.3% overall: 99.3% for the groin, 95.3% for the axilla, and 84.5% for the neck basins."
      },
      "Harms": {
        "score": 1,
        "evidence": "The low (10.1%) complication rate after LM/SNB increased to 37.2% with the addition of CLND; CLND also increased the severity of complications."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}